Aqeuous humor cytokines concentration changes in patients with diabetic macular edema after intravitreal pharmacotherapy
https://doi.org/10.21516/2072-0076-2023-16-2-124-129
Abstract
Purpose: to analyze intraocular fluid (IOF) cytokine concentrations in patients with diabetic macular edema (DME) after intravitreal therapy with angiogenesis inhibitors or corticosteroids (CS).
Materials and methods. 44 patients (45 eyes) were divided in 2 groups depending on the therapy: group 1 (n = 19) received an angiogenesis inhibitor (aflibercept) while group2 (n = 26) received CS (dexamethasone implant). They were tested for IOF cytokine levels by Milliplex® Map Human Cytokine/Chemokine Panel at treatment start and 3 months after either 3 monthly injections of aflibercept or a single dexamethasone implant injection.
Results. The concentrations of ten cytokines (IL-8/CXCL8, IP-10/CXCL10, MCP-1/CCL2, PDGF-AA, GROα/CXCL1, VEGF-A, MIP-1β/CCL4, IL-15, IL-7, IL-6) were found to fall significantly in both groups of therapy. IL-6 and IL-5 levels showed the most significant drop as compared to other cytokines, with a more pronounced decrease in the aflibercept treatment group. In both groups, VEGF-A concentration showed a significant drop, and the share of the eyes that responded to the treatment was 94.7 % in the aflibercept therapy group and 96.2 % in in the dexamethasone implant group.
Conclusion. The IOF concentration assessment of a number of pro-inflammatory cytokines/chemokines shows that both the anti-VEGF agent — aflibercept and CS — dexamethasone implant contribute to a decrease of inflammation which is observed 3 months after the start of treatment.
About the Authors
A. Zh. Fursova
Novosibirsk Regional Hospital;
Novosibirsk State Medical University
Russian Federation
Russian Federation
Anzhella Zh. Fursova, Dr. of Med. Sci., head of the ophthalmological department, 130, Nemirovich-Danchenko St., Novosibirsk, 630087;
head of chair of ophthalmology, 52, Krasny Prospect, Novosibirsk, 630091
A. S. Derbeneva
Novosibirsk Regional Hospital;
Novosibirsk State Medical University
Russian Federation
Russian Federation
Anna S. Derbeneva, ophthalmologist, 130, Nemirovich-Danchenko St., Novosibirsk, 630087;
assistant of chair of ophthalmology, 52, Krasny Prospect, Novosibirsk, 630091
I. M. Amir
Novosibirsk Regional Hospital
Russian Federation
Russian Federation
Inna M. Amir, ophthalmologist,
130, Nemirovich-Danchenko St., Novosibirsk, 630087
O. S. Kozhevnikova
Federal Research Center Institute of Cytology and Genetics, Siberian Branch of the Russian Academy of Sciences
Russian Federation
Russian Federation
Оuna S. Kozhevnikova, leading researcher,
10, Lavrentyev Ave., Novosibirsk, 630090
D. V. Telegina
Federal Research Center Institute of Cytology and Genetics, Siberian Branch of the Russian Academy of Sciences
Russian Federation
Russian Federation
Daria V. Telegina, researcher,
10, Lavrentyev Ave., Novosibirsk, 630090
V. A. Devyatkin
Federal Research Center Institute of Cytology and Genetics, Siberian Branch of the Russian Academy of Sciences
Russian Federation
Russian Federation
Vasily А. Devyatkin, researcher,
10, Lavrentyev Ave., Novosibirsk, 630090
References
1. Schmidt-Erfurth U, Garcia-Arumi J, Bandello F, et al. Guidelines for the management of diabetic macular edema by the European Society of Retina Specialists (EURETINA). Ophthalmologica. 2017; 237 (4): 185–222. https://doi.org/10.1159/000458539
2. Noma H, Yasuda K, Shimura M. Involvement of cytokines in the pathogenesis of diabetic macular edema. Int J Mol Sci. 2021; 22 (7): 3427. doi: 10.3390/ijms22073427
3. Imazeki M, Noma H, Yasuda K, et al. Anti-VEGF therapy reduces inflammation in diabetic macular edema. Ophthalmic Res. 2021; 64 (1): 43–9. doi: 10.1159/000508953
4. Фурсова А.Ж., Дербенева А.С., Амир И.М. и др. Исследование влияния интравитреальной терапии на локальную и системную продукцию цитокинов при диабетическом макулярном отеке. Российский офтальмологический журнал. 2023; 16 (1): 127–34. https://doi.org/10.21516/2072-0076-2023-16-1-127-134
5. Frank RN, Amin RH, Eliott D, et al. Basic fibroblast growth factor and vascular endothelial growth factor are present in epiretinal and choroidal neovascular membranes. Am. J. Ophthalmol. 1996; 122 (3): 393–403. doi: 10.1016/s0002- 9394(14)72066-5
6. Otani A, Takagi H, Oh H, et al. Vascular endothelial growth factor family and receptor expression in human choroidal neovascular membranes. Microvasc Res. 2002; 64 (1): 162–9. doi: 10.1006/mvre.2002.2407
7. Sawada O, Kawamura H, Kakinoki M, et al. Vascular endotelial growth factor in aqueous humor before and after intravitreal injection of bevacizumab in eyes with diabetic retinopathy. Arch Ophthalmol. 2007; 125 (10): 1363–6. doi: 10.1001/archopht.125.10.1363
8. de Freitas LGA, Isaac DLC, Abud MB, et al. Analysis of cytokines in the aqueous humor during intravitreal Ranibizumab treatment of diabetic macular edema. Sci Rep. 2021; 11 (1): 23981. doi: 10.1038/s41598-021-03433-2
9. Wei Q, Wan Z, Hu Y, Peng Q. Cytokine and chemokine profile changes in patients after intravitreal conbercept injection for diabetic macular edema. Drug Des Devel Ther. 2019; 13: 4367–74. doi: 10.2147/DDDT.S222004
10. Campochiaro PA, Wykoff CC, Shapiro H, et al. Neutralization of vascular endothelial growth factor slows progression of retinal nonperfusion in patients with diabetic macular edema. Ophthalmology. 2014; 121 (9): 1783–9. doi: 10.1016/j.ophtha.2014.03.021
11. Hillier RJ, Ojaimi E, Wong DT, et al. Aqueous humor cytokine levels and anatomic response to intravitreal ranibizumab in diabetic macular edema. JAMA Ophthalmol. 2018; 136 (4): 382–8. doi: 10.1001/jamaophthalmol.2018.0179
12. Podkowinski D, Orlowski-Wimmer E, Zlabinger G, et al. Aqueous humour cytokine changes during a loading phase of intravitreal ranibizumab or dexamethasone implant in diabetic macular oedema. Acta Ophthalmol. 2020; 98 (4): 407–15. doi: 10.1111/aos.14297
13. Zhu Y, Li J, Yu S, Mao B, Ying J. Clinical comparative study of intravitreal injection of triamcinolone acetonide and aflibercept in the treatment of diabetic retinopathy cystoid macular edema. Emerg Med Int. 2022; 18: 1348855. doi: 10.1155/2022/1348855
Review
For citations:
Fursova A.Zh., Derbeneva A.S., Amir I.M., Kozhevnikova O.S., Telegina D.V., Devyatkin V.A. Aqeuous humor cytokines concentration changes in patients with diabetic macular edema after intravitreal pharmacotherapy. Russian Ophthalmological Journal. 2023;16(2):124-129. (In Russ.) https://doi.org/10.21516/2072-0076-2023-16-2-124-129
Views:
369
Email this article 